S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Why do tech stocks go down when interest rates rise?
Pure Storage stock fumbles for a rare buying opportunity
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
Bitcoin has surpassed $41,000 for the first time since April 2022. What's behind the price surge?
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

$0.83
+0.07 (+9.21%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.75
$0.84
50-Day Range
$0.46
$0.83
52-Week Range
$0.43
$2.78
Volume
79,693 shs
Average Volume
206,114 shs
Market Capitalization
$14.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.63

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
457.2% Upside
$4.63 Price Target
Short Interest
Healthy
4.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$8,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

125th out of 952 stocks

Pharmaceutical Preparations Industry

42nd out of 434 stocks


ACRX stock logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

ACRX Stock Price History

ACRX Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
AcelRx CEO buys 10,000 shares
Positive Report for Acelrx (ACRX) from H.C. Wainwright
Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call
ACRX - AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals (NASDAQ: ACRX)
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.63
High Stock Price Target
$5.00
Low Stock Price Target
$4.25
Potential Upside/Downside
+457.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$47.76 million
Pretax Margin
-3,711.25%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share

Miscellaneous

Free Float
16,443,000
Market Cap
$14.07 million
Optionable
Optionable
Beta
0.64
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Vincent J. Angotti (Age 55)
    CEO & Director
    Comp: $906.54k
  • Dr. Pamela Pierce Palmer M.D. (Age 60)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $699.75k
  • Mr. Raffi Mark Asadorian (Age 54)
    Chief Financial Officer
    Comp: $637.5k
  • Mr. Anil N. Dasu (Age 60)
    Chief Engineering Officer
    Comp: $478.09k














ACRX Stock Analysis - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings
or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 12 month target prices for AcelRx Pharmaceuticals' shares. Their ACRX share price targets range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next year. This suggests a possible upside of 457.2% from the stock's current price.
View analysts price targets for ACRX
or view top-rated stocks among Wall Street analysts.

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 on January 1st, 2023. Since then, ACRX stock has decreased by 63.3% and is now trading at $0.83.
View the best growth stocks for 2023 here
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The specialty pharmaceutical company had revenue of $0.12 million for the quarter.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals shares reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (0.71%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACRX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -